Menu
Start Here

Short-acting psychedelic

5-MeO-DMT: what the evidence shows

Two positive Phase 2b trials in treatment-resistant depression; Phase 3 has begun. A very short-acting psychedelic, given as a nasal spray (BPL-003) or inhaled (GH001) in trials.

Not an approved treatment for any condition yet.

Last reviewed 23 October 2026Re-checked every month1 conditions with published evidence

Is 5-MeO-DMT legal where you live?See country-by-country rules on our Psychedelic Therapy Legality Map

Condition by condition

One card per condition, strongest evidence first. Hover or tap a label to see what it means; the numbers link to sources at the bottom of the page.

Treatment-resistant depression

Late-stage trials · in progress

Two positive Phase 2b trials; Phase 3 started in 2026.

In a placebo-controlled Phase 2b trial of 81 people, published in JAMA Psychiatry, inhaled GH001 cut depression scores by 15.5 points more than placebo after 8 days; 58% were in remission, versus none on placebo.1

The FDA lifted its US clinical hold on GH001 in January 2026.2

Intranasal BPL-003 met its main goal in a 193-person Phase 2b trial. An earlier open-label study in 12 people found most were ready to go home about 1.5 hours after the dose.34

BPL-003's Phase 3 programme (ReConnection-1 and -2) was initiated in mid-2026, with results expected in early 2029. Eli Lilly agreed to buy the developer in July 2026.567

GH Research still plans to start its own Phase 3 in 2026.8

Compare every substance for treatment-resistant depression →

Keep reading

5-MeO-DMT for Mental Health and TransformationHow 5-MeO-DMT works, effects and duration, therapeutic research, contraindications and legal status.Read the article DMT Study Offers Hope In Fight Against DepressionIn a Phase 2 trial, one DMT session led to 29% remission at two weeks, versus 12% on placebo.Read the article Can Non-Hallucinogenic Psychoplastogens Deliver the Therapeutic Signal?Drugs that promise psychedelics' brain-rewiring effects without the trip. Can plasticity alone do the work?Read the article Research databaseNew studies, summarisedHundreds of papers on psychedelics and mental health, each with a plain-language summary and key facts.Browse the database

Sources

Numbered in the order they appear above. We only use peer-reviewed papers, official company announcements (for trial status and topline results), regulators and trial registries.

  1. Cubała WJ et al. GH001 vs placebo in patients with treatment-resistant depression: a randomized clinical trial. JAMA Psychiatry. 2026Journal
  2. GH Research press release, 5 January 2026Company release
  3. atai Life Sciences and Beckley Psytech press release, 2025Company release
  4. Roberts C et al. A phase 2 uncontrolled, open-label study of intranasal BPL-003 (5-methoxy-N,N-dimethyltryptamine) in patients with treatment-resistant depression. J Psychopharmacol. 2026Journal
  5. AtaiBeckley press release, 12 May 2026Company release
  6. AtaiBeckley press release, 6 July 2026Company release
  7. Eli Lilly and Company press release, 16 July 2026Company release
  8. GH Research press release, 6 August 2026Company release